James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics AG, filed a Form 4 on October 28, 2026, disclosing the grant of stock options and restricted stock units on October 26, 2026.

Key Highlights

  • Stock option grant: Kasinger received a stock option (right to buy) for 18,000 Common Shares at an exercise price of $49.01, expiring October 26, 2036.
  • RSU grant: Kasinger also received 9,000 restricted stock units, each representing a contingent right to receive one CRISPR Therapeutics Common Share.
  • Option vesting schedule: 100% of the 18,000 option shares vest in 48 equal monthly installments, with the first vesting date of November 26, 2026.
  • RSU vesting schedule: The 9,000 RSUs vest in four equal annual installments: one quarter each on October 26, 2027, October 26, 2028, October 26, 2029, and October 26, 2030.
  • Price of derivative securities: Both awards were acquired at a price of $0, as reported in the filing.
  • Ownership form: Both the stock option and RSU award are held directly by the reporting person.

Kasinger's October 2026 Equity Awards: Option and RSU Details

According to the Form 4 filed with the SEC on October 28, 2026, James R. Kasinger, identified as General Counsel and Secretary of CRISPR Therapeutics AG (NASDAQ:CRSP), reported two derivative security transactions dated October 26, 2026. Both awards were acquired, with transaction code "A," and neither involved any non-derivative securities in Table I of the filing.

The stock option grant covers 18,000 Common Shares at a conversion or exercise price of $49.01, with an expiration date of October 26, 2036. As disclosed in the filing's footnotes, "100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 26, 2026." Following the transaction, Kasinger directly holds 18,000 shares underlying this option.

The restricted stock unit award covers 9,000 Common Shares. The filing states that each RSU "represents a contingent right to receive one share of CRSP Common Shares." The RSUs are scheduled to vest annually in four equal portions: one quarter on each of October 26, 2027, October 26, 2028, October 26, 2029, and October 26, 2030. Following this transaction, Kasinger directly holds 9,000 RSUs. The Form 4 was signed by Elizabeth Ryland Waldinger as attorney-in-fact on October 28, 2026.

What Was Disclosed

The filing disclosed two equity awards granted to James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics AG, on October 26, 2026: a stock option covering 18,000 Common Shares at $49.01 per share and an RSU award covering 9,000 Common Shares, both held directly.